Genprex, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GNPX research report →
Price Chart
About the company
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes.
- CEO
- Ryan Confer
- IPO
- 2018
- Employees
- 13
- HQ
- Austin, TX, US
Get TickerSpark's AI analysis on GNPX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $732.16K
- P/E
- -0.03
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.10
- EV/EBITDA
- 0.87
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -126.83%
- ROIC
- -122.17%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-15,515,619
- Net Income
- $-16,228,953+23.1%
- EPS
- $-382.80+93.5%
- OCF Growth
- +10.7%
- FCF Growth
- +10.7%
- 52W High
- $80.96
- 52W Low
- $1.45
- 50D MA
- $2.48
- 200D MA
- $16.30
- Beta
- -0.99
- RSI (14)
- 27
- Avg Volume
- 168.88K
No earnings-call transcripts are available for GNPX yet.
- Free Float
- 95.1%
- Shares Outstanding
- 504.94K
- Float Shares
- 480.21K
of shares held by institutions
25 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for GNPX, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Engineers Gate Manager LP | 20.89K | ▲ 20.89K |
| Vanguard Fiduciary Trust Co | 3.55K | ▼ 74.55K |
| Tower Research Capital LLC (Trc) | 2.85K | ▲ 2.85K |
| Vanguard Capital Management LLC | 1.65K | ▼ 34.70K |
| Ubs Group AG | 443 | ▼ 4.05K |
| Jones Financial Companies Lllp | 56 | ▼ 1.15K |
| Cheviot Value Management, LLC | 46 | ▼ 954 |
| Bernard Wealth Management Corp. | 30 | ▼ 170 |
| Integrated Wealth Concepts LLC | 21 | ▲ 21 |
| Blackrock, Inc. | 10 | ▼ 178 |
| Highmark Wealth Management LLC | 10 | 0 |
| Osaic Holdings, Inc. | 8 | ▼ 74 |
Held by 5 ETFs
Biggest fund positions in GNPX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 14, 26 | LONGNECKER BRENT M | sell | 8 |
| Apr 14, 26 | LONGNECKER BRENT M | sell | 10 |
| Feb 27, 26 | Berger Mark Stanley | other | 7,168 |
| Feb 27, 26 | Confer Ryan M. | other | 9,330 |
| Dec 22, 25 | Moreno Toscano Jose Antonio | other | 9,000 |
| Dec 22, 25 | Berger Mark Stanley | other | 28,500 |
| Dec 22, 25 | Confer Ryan M. | other | 45,000 |
| Dec 22, 25 | LONGNECKER BRENT M | other | 9,000 |
| Dec 22, 25 | Wilson William R Jr. | other | 9,000 |
| Jun 30, 25 | Berger Mark Stanley | other | 4,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GNPX coverage
Recent articles, reports, and earnings notes.
No research on GNPX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GNPX report →Genprex Presents Preclinical Data Identifying TROP2 as a Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung Cancer
prnewswire.com · Nov 19
Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium
prnewswire.com · Nov 11
Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress
prnewswire.com · Nov 5
Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer
prnewswire.com · Nov 4
Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting
prnewswire.com · Oct 28
Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging
prnewswire.com · Oct 21
Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference
prnewswire.com · Sep 8
Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy
prnewswire.com · Aug 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.